Supplementary Table S7 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

Supplementary Table S7 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

<p>Supplementary Table S7. DEGs for 1 month Comparison of CD49d+ and CD49d-</p>

保存先:

書誌詳細
第一著者:	Anfal Alsadhan (15907475) (author)
その他の著者:	Jonathan Chen (15907478) (author), Erika M. Gaglione (15032498) (author), Chingiz Underbayev (15907481) (author), Pamela L. Tuma (15907484) (author), Xin Tian (15907487) (author), Lita A. Freeman (15907490) (author), Sivasubramanian Baskar (15907493) (author), Pia Nierman (15907496) (author), Susan Soto (15907499) (author), Andy Itsara (15907502) (author), Inhye E. Ahn (15032501) (author), Clare Sun (14953020) (author), Elena Bibikova (15907505) (author), Tanja Nicole Hartmann (15907508) (author), Maissa Mhibik (15907511) (author), Adrian Wiestner (15907514) (author)
出版事項:	2025
主題:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Immuno-oncology Cell Signaling Cell adhesion Protein tyrosine kinases Drug Resistance Hematological Cancers Leukemias Lymphomas Immunology Immunomodulation
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Supplementary Table S10 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
著者:: Anfal Alsadhan (15907475)
出版事項: (2025)

Supplementary Table S4 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
著者:: Anfal Alsadhan (15907475)
出版事項: (2025)

Supplementary Table S5 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
著者:: Anfal Alsadhan (15907475)
出版事項: (2025)

Supplementary Table S6 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
著者:: Anfal Alsadhan (15907475)
出版事項: (2025)

Supplementary Table S8 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
著者:: Anfal Alsadhan (15907475)
出版事項: (2025)

Supplementary Table S9 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
著者:: Anfal Alsadhan (15907475)
出版事項: (2025)

Table S9 from Cross-talk between Myeloid and B Cells Shapes the Distinct Microenvironments of Primary and Secondary Liver Cancer
著者:: Zhihang Chen (17315678)
出版事項: (2025)

Data Sheet 1_Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic NSCLC.docx
著者:: Xinhang Gu (22686224)
出版事項: (2025)

Table S1 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
著者:: Ruth Flümann (15123900)
出版事項: (2025)

Table S2 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
著者:: Ruth Flümann (15123900)
出版事項: (2025)

Table S3 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
著者:: Ruth Flümann (15123900)
出版事項: (2025)

Table S4 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
著者:: Ruth Flümann (15123900)
出版事項: (2025)

Table S5 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
著者:: Ruth Flümann (15123900)
出版事項: (2025)

Table S6 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
著者:: Ruth Flümann (15123900)
出版事項: (2025)

Table S1 from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8<sup>+</sup> T Cells
著者:: Snehanshu Chowdhury (14957031)
出版事項: (2025)

Figure S1 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
著者:: Upendra Kumar Soni (15051683)
出版事項: (2025)

Figure S2 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
著者:: Upendra Kumar Soni (15051683)
出版事項: (2025)

Figure S3 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
著者:: Upendra Kumar Soni (15051683)
出版事項: (2025)

Figure S4 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
著者:: Upendra Kumar Soni (15051683)
出版事項: (2025)

Figure S5 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
著者:: Upendra Kumar Soni (15051683)
出版事項: (2025)

Figure S6 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
著者:: Upendra Kumar Soni (15051683)
出版事項: (2025)

Supplementary Data File S1 from Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition
著者:: Upendra Kumar Soni (15051683)
出版事項: (2025)

Supplementary Data from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy
著者:: Ti Wen (15130158)
出版事項: (2025)

Supplementary Table S1 from A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer
著者:: Nan Ding (15321526)
出版事項: (2025)

Supplementary Table S2 from A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer
著者:: Nan Ding (15321526)
出版事項: (2025)

Filamin A KO and S2152A KI reduce KSHV de novo infection of cell-free virions.
著者:: Xiaojuan Li (351842)
出版事項: (2025)

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
著者:: Erika Y. Faraoni (14844897)
出版事項: (2025)

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
著者:: Erika Y. Faraoni (14844897)
出版事項: (2025)

Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
著者:: Erika Y. Faraoni (14844897)
出版事項: (2025)

Supplementary Tables from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
著者:: Francesco Maura (15022226)
出版事項: (2025)

Figure 1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
著者:: Ernesto Gargiulo (15134961)
出版事項: (2025)

Figure 2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
著者:: Ernesto Gargiulo (15134961)
出版事項: (2025)

Figure 3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
著者:: Ernesto Gargiulo (15134961)
出版事項: (2025)

Figure 4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
著者:: Ernesto Gargiulo (15134961)
出版事項: (2025)

Figure 5 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
著者:: Ernesto Gargiulo (15134961)
出版事項: (2025)

Figure 6 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
著者:: Ernesto Gargiulo (15134961)
出版事項: (2025)

Figure 7 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
著者:: Ernesto Gargiulo (15134961)
出版事項: (2025)

Supplementary Table S1 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
著者:: Jonathan M.J. Derry (16648337)
出版事項: (2025)

Supplementary Table S2 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
著者:: Jonathan M.J. Derry (16648337)
出版事項: (2025)

Supplementary Table S3 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
著者:: Jonathan M.J. Derry (16648337)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_lsk44npuquf04dn3e06vr227qf